All In Biotech

Drug Trial Radar · NCT01694849

Phase IIb Study to Evaluate the Efficacy and Safety of GFT505 Versus Placebo in Patients With Non-Alcoholic Steatohepatitis (NASH)

A Multicentre, Randomized, Double Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of GFT505 Once Daily on Steatohepatitis in Patients With Non-Alcoholic Steatohepatitis (NASH).

Last checked: Nov 19, 2026Latest source record: Nov 3, 2022 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingRandomized with 275 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

275

Actual

Start

Sep 2012

Primary completion

Feb 2015

Study completion Dec 2015

Sponsor

Lead sponsor
GenfitIndustry
Sponsor type
Industry
Collaborators
Naturalpha; Premier Research
First posted
Sep 27, 2012

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
Who can join
All sexes, from 18 years, up to 75 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

Abdominal obesity and type-2 Diabetes are associated with chronic liver disorders resulting from the accumulation of fat in the liver (steatosis), which may progress towards hepatitis and possibly lead to cirrhosis and liver cancer. NAFLD (Non Alcoholic Fatty Liver Disease) is considered as the most common form of chronic liver disease in adults in the United States, Australia, Asia and Europe. In the USA, the estimated prevalence of NAFLD is 20-30% of the adult population. Non-alcoholic Steatohepatitis (NASH) is a progressing form of NAFLD, which corresponds to hepatic steatosis associated with inflammation and liver cell injury upon microscopic examination of a liver biopsy. This condition may lead to advanced fibrosis and cirrhosis and deserves serious medical management. Up to now, there is no effective drug which has clearly demonstrated therapeutic efficacy which may help lifestyle and dietary recommendations in the resolution of NASH. In this context, GENFIT is developing a new liver targeted drug candidate, GFT505, for the treatment of NASH and the reduction of multiple cardiometabolic risk factors associated with the metabolic syndrome and type 2 Diabetes. This phase IIb study will evaluate the efficacy and safety of GFT505 80mg and 120mg once daily for 52 weeks on the reversal of NASH without worsening of fibrosis, based on liver biopsy assessments.

Conditions

  • Non-Alcoholic Steatohepatitis (NASH)

Interventions

  • GFT505 80mgDrug

  • GFT505 120mgDrug

  • PlaceboDrug

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Percentage of Responders With Disappearance of Steatohepatitis Without Worsening of Fibrosis (ie, Participants no Longer Meeting the Criteria for Steatohepatitis)Time frame: Baseline (Visit 2; Week 0) to Visit 8 (Week 52)

Locations

56 sites in 9 countries. Site status is shown where the registry gives one.

  • Site 920

    Fresno, California

  • Site 903

    La Jolla, California

  • Site 911

    Aurora, Colorado

  • Site 912

    Gainesville, Florida

  • Site 924

    Atlanta, Georgia

  • Site 917

    Atlanta, Georgia

  • Site 909

    New Orleans, Louisiana

  • Site 921

    Worcester, Massachusetts

  • Site 902

    Detroit, Michigan

  • Site 927

    New York, New York

  • Site 908

    Durham, North Carolina

  • Site 919

    Philadelphia, Pennsylvania

  • Site 916

    Memphis, Tennessee

  • Site 913

    Fort Sam Houston, Texas

  • Site 923

    Houston, Texas

  • Site 906

    San Antonio, Texas

  • Site 931

    Salt Lake City, Utah

  • Site 930

    Charlottesville, Virginia

  • Site 901

    Richmond, Virginia

  • Site 205

    Brussels, Belgium

  • Site 201

    Edegem, Belgium

  • Site 204

    Ghent, Belgium

  • Site 202

    Haine-Saint-Paul, Belgium

  • Site 203

    Leuven, Belgium

  • Site 106

    Amiens, France

  • Site 102

    Angers, France

  • Site 114

    Clichy, France

  • Site 103

    Lille, France

  • Site 113

    Lyon, France

  • Site 111

    Marseille, France

  • Site 108

    Montpellier, France

  • Site 104

    Nantes, France

  • Site 109

    Nice, France

  • Site 112

    Paris, France

  • Site 101

    Paris, France

  • Site 107

    Pessac, France

  • Site 405

    Bonn, Germany

  • Site 404

    Mainz, Germany

  • Site 507

    Milan, Italy

  • Site 503

    Palermo, Italy

Showing 40 of 56 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.